Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091690 | 0.85 | ELANE (0.53) | ELANEALDH1A1PPARAGAAL3MBTL1 | |
| SCHEMBL465078 | 0.83 | LTA4H (0.44) | ALDH1A1GAAHTTSMN1; SMN2LMNA | |
| SCHEMBL3093634 | 0.79 | ALDH1A1 (0.48) | ELANEALDH1A1PPARARAB9AHTT | |
| SCHEMBL2696251 | 0.77 | LTA4H (0.43) | ALDH1A1HTTSMN1; SMN2LMNAMAPK1 | |
| SCHEMBL50280 | 0.77 | GAA (0.72) | ELANEPPARAGAAL3MBTL1LMNA | |
| SCHEMBL701779 | 0.76 | LTA4H (0.47) | ALDH1A1GAAHTTSMN1; SMN2LMNA | |
| SCHEMBL2120697 | 0.76 | LMNA (0.49) | L3MBTL1LMNAMAPK1MEN1KMT2A | |
| SCHEMBL3093028 | 0.75 | ELANE (0.44) | ELANEALDH1A1PPARAGAAL3MBTL1 | |
| SCHEMBL14306195 | 0.74 | PPARA (0.71) | PPARAGAAL3MBTL1LMNAMAPT | |
| Benzophenone SCHEMBL23014697 | 0.74 | ALDH1A1 (0.67) | ELANEALDH1A1L3MBTL1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318830-B2 | Photolatent catalysts based on organometallic compounds | BASF SE (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20100234485-A1 | PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS | BASF SE (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234485-A1 | PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS | PUF60, TST, MPST | ELANE 1873/4885ALDH1A1 1432/4885PPARA 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.